Hyperinsulinemia Can Cause Kidney Disease in the IGT Stage of OLETF Rats via the INS/IRS-1/PI3-K/Akt Signaling Pathway

高胰岛素血症可通过 INS/IRS-1/PI3-K/Akt 信号通路导致 OLETF 大鼠 IGT 阶段出现肾脏疾病

阅读:7
作者:Yi Zhang, Shaohua Yang, Xiao Cui, Juhong Yang, Miaoyan Zheng, Junya Jia, Fei Han, Xiaoyun Yang, Jingyu Wang, Zhenhong Guo, Bai Chang, Baocheng Chang

Aims

We investigated the changes of renal structure and its function in normal glucose tolerance (NGT), impaired glucose tolerance (IGT), diabetes mellitus (DM), and diabetic kidney disease (DKD) stages in OLETF rats and explored the role of the INS/IRS-1/PI3-K/Akt signaling pathway.

Conclusions

In contrast to DKD, the renal structural damage and functional changes in the IGT stage, in which we propose the term "IGT kidney disease," mainly manifest as renal tubular injury. Insulin resistance and compensatory hyperinsulinemia may be involved in its pathogenesis.

Methods

OLETF rats were assigned into four groups on the basis of OGTT

Results

In the IGT group, the index which reflects the function of renal tubule-like N-acetyl-β-glucosaminidase, neutrophil gelatinase-associated lipocalin, retinol-binding protein, and cystatin C was higher than those in the control group and the NGT group (P < 0.05). Significant renal structure damages, especially in renal tubules, were observed in the IGT group. In the presence of insulin at a high concentration, the IRS-1/PI3-K/Akt signaling pathway in renal tubular epithelial cells was inhibited, and the expression of megalin and cubilin was significantly downregulated which was accompanied by a minimum uptake of albumin. Conclusions: In contrast to DKD, the renal structural damage and functional changes in the IGT stage, in which we propose the term "IGT kidney disease," mainly manifest as renal tubular injury. Insulin resistance and compensatory hyperinsulinemia may be involved in its pathogenesis.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。